home / stock / torc / torc news

TORC News and Press, resTORbio Inc. From 10/02/19

Stock Information
Company Name: resTORbio Inc.
Stock Symbol: TORC
Market: NASDAQ
Website: restorbio.com
Menu
TORC TORC Quote TORC Short TORC News TORC Articles TORC Message Board
Get TORC Alerts

News, Short Squeeze, Breakout and More Instantly...
TORC - resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, will present new data today about RTB101, the company’s i...
TORC - resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 2019 Cantor...

TORC - resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek(TM) 2019

BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, has been selected to present new data from its clinical develop...

TORC - Morgan Stanley sees 23% upside in Galapagos in premarket analyst action

Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

TORC - resTORbio (TORC) Presents At Wedbush PacGrow Healthcare Conference - Slideshow

The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...

TORC - resTORbio EPS misses by $0.12

resTORbio (NASDAQ: TORC ): Q2 GAAP EPS of -$0.51 misses by $0.12 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

TORC - resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update

– Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug. 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company...
TORC - resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019

BOSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the company will present a corporate overview at ...

TORC - resTORbio: Strong Results In Phase 2 Makes This Worth A Look

resTORbio, Inc. ( TORC ) is a clinical-stage, specialty biopharmaceutical company. They are developing medicines that target the biology of aging to prevent or treat aging-related diseases. The company's lead product candidate, RTB101, is an orally administered, selective, and potent inhibit...

TORC - resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – BOSTON, July 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ...
Previous 10 Next 10